Close

Arena and Eisai Complete End-of-Review Meeting with FDA

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Role of Combination Products is on the Rise in Biopharma

In the dynamic world of today, role of combination...

Buyout of SpringWorks Brings Back Merck KGaA in the M&A Game

Merck KGaA’s long-standing courtship of SpringWorks Therapeutics has finally...

Roche Looks to Expand its Drug Production in the US

Roche is planning to expand its drug production in...

How Language Barriers Impact Non-Native English Speakers in Healthcare

Language barriers create significant challenges for non-native English speakers...

Arena Pharmaceuticals, Inc. and Eisai Inc. announced today the completion of an end-of-review meeting with the US Food and Drug Administration (FDA) for the lorcaserin New Drug Application (NDA). Jack Lief, Arena’s President and Chief Executive Officer said, The meeting discussions reinforce our position that we have a path forward to seek FDA approval of lorcaserin . Based on guidance we have received from the agency, we are executing several activities and expect to resubmit the lorcaserin NDA by the end of 2011. As we continue discussions with the FDA to refine elements of our plan, we may identify ways to shorten this timeline. We will provide more details about our plan on the conference call and webcast this morning.

Arena submitted an NDA for lorcaserin to the FDA in December 2009, and the FDA issued a Complete Response Letter (CRL) in October 2010. In the CRL, the FDA outlined non-clinical and clinical reasons for its decision and provided recommendations relating to addressing such issues. The end-of-review meeting with the FDA included a discussion of the FDA’s position on issues identified in the CRL and Arena’s plan to respond.

Latest stories

Related stories

Role of Combination Products is on the Rise in Biopharma

In the dynamic world of today, role of combination...

Buyout of SpringWorks Brings Back Merck KGaA in the M&A Game

Merck KGaA’s long-standing courtship of SpringWorks Therapeutics has finally...

Roche Looks to Expand its Drug Production in the US

Roche is planning to expand its drug production in...

How Language Barriers Impact Non-Native English Speakers in Healthcare

Language barriers create significant challenges for non-native English speakers...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back